BRPI0807256A2 - "composição com fórmula geral i, composto com a fórmula ii, anticorpo, método de produção de inibidor de metaloproteinase,composição farmacêutica, método de tratamento de doença associada a atividade incompatível ou anormal de metaloproteinas, método de inibição da atividade da metaloproteinase matriz em uma célula" - Google Patents

"composição com fórmula geral i, composto com a fórmula ii, anticorpo, método de produção de inibidor de metaloproteinase,composição farmacêutica, método de tratamento de doença associada a atividade incompatível ou anormal de metaloproteinas, método de inibição da atividade da metaloproteinase matriz em uma célula" Download PDF

Info

Publication number
BRPI0807256A2
BRPI0807256A2 BRPI0807256-6A2A BRPI0807256A BRPI0807256A2 BR PI0807256 A2 BRPI0807256 A2 BR PI0807256A2 BR PI0807256 A BRPI0807256 A BR PI0807256A BR PI0807256 A2 BRPI0807256 A2 BR PI0807256A2
Authority
BR
Brazil
Prior art keywords
mmp
antibody
activity
methyl
antibodies
Prior art date
Application number
BRPI0807256-6A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Irit Sagi
Tamar Damon
Netta Sela
Abraham Shanzer
Rina Arad-Yellin
Raghavendra Kikkeri
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of BRPI0807256A2 publication Critical patent/BRPI0807256A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/06—Zinc compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0807256-6A2A 2007-02-23 2008-02-21 "composição com fórmula geral i, composto com a fórmula ii, anticorpo, método de produção de inibidor de metaloproteinase,composição farmacêutica, método de tratamento de doença associada a atividade incompatível ou anormal de metaloproteinas, método de inibição da atividade da metaloproteinase matriz em uma célula" BRPI0807256A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90285407P 2007-02-23 2007-02-23
US60/902,854 2007-02-23
PCT/IL2008/000230 WO2008102359A1 (en) 2007-02-23 2008-02-21 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins

Publications (1)

Publication Number Publication Date
BRPI0807256A2 true BRPI0807256A2 (pt) 2014-07-22

Family

ID=39534848

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807256-6A2A BRPI0807256A2 (pt) 2007-02-23 2008-02-21 "composição com fórmula geral i, composto com a fórmula ii, anticorpo, método de produção de inibidor de metaloproteinase,composição farmacêutica, método de tratamento de doença associada a atividade incompatível ou anormal de metaloproteinas, método de inibição da atividade da metaloproteinase matriz em uma célula"

Country Status (11)

Country Link
US (5) US8324355B2 (OSRAM)
EP (1) EP2155691B1 (OSRAM)
JP (2) JP5513130B2 (OSRAM)
KR (1) KR20090113908A (OSRAM)
CN (1) CN101702906B (OSRAM)
BR (1) BRPI0807256A2 (OSRAM)
CA (1) CA2678304A1 (OSRAM)
IL (2) IL224120A (OSRAM)
MX (1) MX2009008914A (OSRAM)
RU (1) RU2503682C2 (OSRAM)
WO (1) WO2008102359A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090113908A (ko) 2007-02-23 2009-11-02 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 금속단백질 활성 억제용 항체 및 이를 함유하는 약학적 조성물
US8147836B2 (en) 2007-12-17 2012-04-03 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
AU2009221916A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8673267B2 (en) * 2009-03-02 2014-03-18 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
CN102822202B (zh) * 2010-01-27 2015-07-22 耶达研究及发展有限公司 抑制金属蛋白的抗体
SI2608809T1 (sl) 2010-08-27 2019-08-30 Gilead Biologics, Inc. Protitelesa proti matriksu metaloproteinaze 9
ES2688457T3 (es) * 2010-10-28 2018-11-02 Yeda Research And Development Co. Ltd. Métodos de generación de anticuerpos contra metaloenzimas
WO2013059439A2 (en) 2011-10-21 2013-04-25 Dyax Corp. Combination therapy comprising an mmp-14 binding protein
AU2013203619B2 (en) 2012-02-29 2015-02-26 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
JP6847660B2 (ja) 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
CN115177588A (zh) 2014-04-03 2022-10-14 瑞士杰特贝林生物制品有限公司 免疫球蛋白的雾化
US10278178B2 (en) 2014-05-19 2019-04-30 Qualcomm Incorporated Apparatus and method for inter-band pairing of carriers for time division duplex transmit- and receive-switching
US11357022B2 (en) 2014-05-19 2022-06-07 Qualcomm Incorporated Apparatus and method for interference mitigation utilizing thin control
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP3424168B1 (en) * 2016-04-04 2022-06-01 Samsung Electronics Co., Ltd. Method and apparatus for transmitting and receiving feedback in wireless communication system
WO2018148595A1 (en) * 2017-02-10 2018-08-16 Washington University Antibodies to tip1 and methods of use thereof
US11519905B2 (en) 2017-04-07 2022-12-06 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
KR102657653B1 (ko) 2017-07-18 2024-04-16 다이이찌 산쿄 가부시키가이샤 활성형 mmp-9 결합 펩티드
US12173349B2 (en) 2018-09-25 2024-12-24 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
US11835522B2 (en) 2019-01-17 2023-12-05 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
IL264768A (en) 2019-02-10 2020-08-31 Sagi Irit ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) inhibitory antibody and its use
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
WO2025075789A1 (en) * 2023-10-03 2025-04-10 Merck Sharp & Dohme Llc Immunoassay for detecting tau phosphorylated at serine 413
WO2025076280A1 (en) 2023-10-05 2025-04-10 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
AU3899193A (en) 1992-04-07 1993-11-08 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
WO1995029892A1 (en) 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
WO1995029689A1 (en) 1994-04-28 1995-11-09 Merck & Co., Inc. N-carboxyalkyl derivatives as antidegenerative active agents
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
KR100231230B1 (ko) 1995-08-08 1999-11-15 우에노 도시오 히드록삼산 유도체(hydroxamic acid derivatives)
IL116126A0 (en) * 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
PT780386E (pt) 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz
ATE262899T1 (de) 1996-01-02 2004-04-15 Aventis Pharma Inc Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen
WO1997049679A1 (en) 1996-06-27 1997-12-31 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
NZ509439A (en) 1998-07-30 2002-10-25 Warner Lambert Co Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
IL178921A0 (en) * 1998-12-24 2007-03-08 Yeda Res & Dev Caspase-8 interacting proteins
DK1610678T3 (da) * 2003-04-04 2011-10-24 Yeda Res & Dev Antistoffer til inhibering af aktiviteten af MMP-2 og MMP-9
KR20090113908A (ko) * 2007-02-23 2009-11-02 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 금속단백질 활성 억제용 항체 및 이를 함유하는 약학적 조성물
CN102822202B (zh) 2010-01-27 2015-07-22 耶达研究及发展有限公司 抑制金属蛋白的抗体

Also Published As

Publication number Publication date
IL224121A (en) 2016-05-31
US20100233188A1 (en) 2010-09-16
US9416195B2 (en) 2016-08-16
US9902783B2 (en) 2018-02-27
CN101702906A (zh) 2010-05-05
US20130030158A1 (en) 2013-01-31
US20130224225A1 (en) 2013-08-29
JP2010519289A (ja) 2010-06-03
JP5513130B2 (ja) 2014-06-04
KR20090113908A (ko) 2009-11-02
CN101702906B (zh) 2014-02-12
CA2678304A1 (en) 2008-08-28
RU2503682C2 (ru) 2014-01-10
US20180134808A1 (en) 2018-05-17
MX2009008914A (es) 2009-08-28
US20160257765A1 (en) 2016-09-08
US8486653B2 (en) 2013-07-16
EP2155691B1 (en) 2016-01-13
US8324355B2 (en) 2012-12-04
WO2008102359A9 (en) 2009-05-22
EP2155691A1 (en) 2010-02-24
JP2013241435A (ja) 2013-12-05
IL224120A (en) 2016-05-31
WO2008102359A1 (en) 2008-08-28
AU2008218525A1 (en) 2008-08-28
RU2009132006A (ru) 2011-02-27
JP5792231B2 (ja) 2015-10-07

Similar Documents

Publication Publication Date Title
BRPI0807256A2 (pt) "composição com fórmula geral i, composto com a fórmula ii, anticorpo, método de produção de inibidor de metaloproteinase,composição farmacêutica, método de tratamento de doença associada a atividade incompatível ou anormal de metaloproteinas, método de inibição da atividade da metaloproteinase matriz em uma célula"
US8841108B2 (en) Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
AU2011210362B2 (en) Antibodies that inhibit metalloproteins
US10066024B2 (en) Methods of generating antibodies to metalloenzymes
AU2008218525B2 (en) Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
HK1142331A (en) Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015.